Practical considerations when treating chronic hepatitis E in solid organ transplant recipients

David K. Choi; Michelle T. Martin; Wadih Chacra; Christine Chan; Sean Koppe; Lisa Landers; Ammara Naveed; Adam E. Mikolajczyk

doi:10.1007/s11096-020-01195-x

Practical considerations when treating chronic hepatitis E in solid organ transplant recipients

David K. Choi^*, Michelle T. Martin, Wadih Chacra, Christine Chan, Sean Koppe, Lisa Landers, Ammara Naveed, Adam E. Mikolajczyk

^*Corresponding author for this work

Medicine, Hepatology Division

Research output: Contribution to journal › Comment/debate › peer-review

Abstract

Hepatitis E virus (HEV) can lead to chronic infections in immunosuppressed patients. The use of ribavirin to treat chronic HEV has been well-established in case reports and guidelines. However, practical approaches to the use of this antiviral treatment in a post-transplant patient, including drug interactions, dosing adjustments, and monitoring parameters, are lacking. Thus, we present our real-world approach to the use of ribavirin to treat chronic HEV in a solid organ transplant recipient.

Original language	English (US)
Pages (from-to)	753-755
Number of pages	3
Journal	International Journal of Clinical Pharmacy
Volume	43
Issue number	3
DOIs	https://doi.org/10.1007/s11096-020-01195-x
State	Published - Jun 2021

Keywords

Hepatitis E virus
Liver transplant
Ribavirin
Transplant

ASJC Scopus subject areas

Pharmacy
Toxicology
Pharmacology
Pharmaceutical Science
Pharmacology (medical)

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1007/s11096-020-01195-x

Cite this

@article{00b53d1f34f4425580f371af4ea5edb0,

title = "Practical considerations when treating chronic hepatitis E in solid organ transplant recipients",

abstract = "Hepatitis E virus (HEV) can lead to chronic infections in immunosuppressed patients. The use of ribavirin to treat chronic HEV has been well-established in case reports and guidelines. However, practical approaches to the use of this antiviral treatment in a post-transplant patient, including drug interactions, dosing adjustments, and monitoring parameters, are lacking. Thus, we present our real-world approach to the use of ribavirin to treat chronic HEV in a solid organ transplant recipient.",

keywords = "Hepatitis E virus, Liver transplant, Ribavirin, Transplant",

author = "Choi, {David K.} and Martin, {Michelle T.} and Wadih Chacra and Christine Chan and Sean Koppe and Lisa Landers and Ammara Naveed and Mikolajczyk, {Adam E.}",

note = "Publisher Copyright: {\textcopyright} 2020, Springer Nature Switzerland AG.",

year = "2021",

month = jun,

doi = "10.1007/s11096-020-01195-x",

language = "English (US)",

volume = "43",

pages = "753--755",

journal = "International Journal of Clinical Pharmacy",

issn = "2210-7703",

publisher = "Springer Science and Business Media Deutschland GmbH",

number = "3",

}

TY - JOUR

T1 - Practical considerations when treating chronic hepatitis E in solid organ transplant recipients

AU - Choi, David K.

AU - Martin, Michelle T.

AU - Chacra, Wadih

AU - Chan, Christine

AU - Koppe, Sean

AU - Landers, Lisa

AU - Naveed, Ammara

AU - Mikolajczyk, Adam E.

PY - 2021/6

Y1 - 2021/6

N2 - Hepatitis E virus (HEV) can lead to chronic infections in immunosuppressed patients. The use of ribavirin to treat chronic HEV has been well-established in case reports and guidelines. However, practical approaches to the use of this antiviral treatment in a post-transplant patient, including drug interactions, dosing adjustments, and monitoring parameters, are lacking. Thus, we present our real-world approach to the use of ribavirin to treat chronic HEV in a solid organ transplant recipient.

AB - Hepatitis E virus (HEV) can lead to chronic infections in immunosuppressed patients. The use of ribavirin to treat chronic HEV has been well-established in case reports and guidelines. However, practical approaches to the use of this antiviral treatment in a post-transplant patient, including drug interactions, dosing adjustments, and monitoring parameters, are lacking. Thus, we present our real-world approach to the use of ribavirin to treat chronic HEV in a solid organ transplant recipient.

KW - Hepatitis E virus

KW - Liver transplant

KW - Ribavirin

KW - Transplant

UR - http://www.scopus.com/inward/record.url?scp=85095721349&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85095721349&partnerID=8YFLogxK

U2 - 10.1007/s11096-020-01195-x

DO - 10.1007/s11096-020-01195-x

M3 - Comment/debate

C2 - 33169803

AN - SCOPUS:85095721349

SN - 2210-7703

VL - 43

SP - 753

EP - 755

JO - International Journal of Clinical Pharmacy

JF - International Journal of Clinical Pharmacy

IS - 3

ER -

Practical considerations when treating chronic hepatitis E in solid organ transplant recipients

Abstract

Keywords

ASJC Scopus subject areas

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this